Telomeres and essential hypertension

Clinical Biochemistry

Volumn 48, Issue 16-17, 2015, Pages 1195-1199

  Ma, Lina ^a   Li, Yun ^a   Wang, Jieyu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Hypertension; Telomerase; Telomere length

Indexed keywords

TELOMERASE;

ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; GENETIC PARAMETERS; HUMAN; MEDLINE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TELOMERE; TELOMERE LENGTH; ANIMAL; HYPERTENSION; METABOLISM;

ANIMALS; HUMANS; HYPERTENSION; TELOMERASE; TELOMERE;

EID: 84947040079     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.07.013     Document Type: Review

References (44)

1. Ardalan M.R., Rafieian-Kopaei M. Antioxidant supplementation in hypertension. J. Renal Inj. Prev. 2013, 3(2):39-40.
2. World Health Organization Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks 2009.
3. Awad M., Ruzza A., Mirocha J., Setareh-Shenas S., Pixton J.R., Soliman C., Czer L.S. Prevalence of hypertension in the Gambia and Sierra Leone, western Africa: a cross-sectional study. Cardiovasc. J. Afr. 2014, 25:1-10.
4. Lim S.S., Vos T., Flaxman A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
5. M'kacher R., Girinsky T., Colicchio B., Ricoul M., Dieterlen A., Jeandidier E., et al. Telomere shortening: a new prognostic factor for cardiovascular disease post-radiation exposure. Radiat. Prot. Dosimetry 2015, 164(1-2):134-137.
6. Fyhrquist F., Saijonmaa O., Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat. Rev. Cardiol. 2013, 10(5):274-283.
7. Alter B.P., Giri N., Savage S.A., Rosenberg P.S. Telomere length in inherited bone marrow failure syndromes. Haematologica 2015, 100(1):49-54.
8. Drapkina O.M., Shepel' R.N. Telomeres and chronic heart failure. Kardiologiia 2014, 54(4):60-67.
9. Gardner M., Bann D., Wiley L., Cooper R., Hardy R., Nitsch D., et al. Gender and telomere length: systematic review and meta-analysis. Exp. Gerontol. 2014, 51:15-27.
10. Zhang D.H., Wen X.M., Zhang L., Cui W. DNA methylation of human telomerase reverse transcriptase associated with leukocyte telomere length shortening in hyperhomocysteinemia-type hypertension in humans and in a rat model. Circ. J. 2014, 78(8):1915-1923.
11. Cao Y., Li H., Mu F.T., et al. Telomerase activation causes vascular smooth muscle cell proliferation in genetic hypertension. FASEB J. 2002, 16(1):96-98.
12. Pérez-Rivero G., Ruiz-Torres M.P., Rivas-Elena J.V., Jerkic M., Díez-Marques M.L., Lopez-Novoa J.M., et al. Mice deficient in telomerase activity develop hypertension because of an excess of endothelin production. Circulation 2006, 114(4):309-317.
13. Insel K.C., Merkle C.J., Hsiao C.P., Vidrine A.N., Montgomery D.W. Biomarkers for cognitive aging part I: telomere length, blood pressure and cognition among individuals with hypertension. Biol. Res. Nurs. 2012, 14(2):124-132.
14. Bhupatiraju C., Saini D., Patkar S., Deepak P., Das B., Padma T. Association of shorter telomere length with essential hypertension in Indian population. Am. J. Hum. Biol. 2012, 24(4):573-578.
15. Maeda T., Oyama J.I., Sasaki M., Arima T., Makino N. The correlation between the clinical laboratory data and the telomere length in peripheral blood leukocytes of Japanese female patients with hypertension. J. Nutr. Health Aging 2011, 15(3):240-244.
16. Huber M., Treszl A., Wehland M., Winther I., Zergibel I., Reibis R., et al. Genetic variants implicated in telomere length associated with left ventricular function in patients with hypertension and cardiac organ damage. J. Mol. Med. (Berl.) 2012, 90(9):1059-1067.
17. Morgan R.G., Ives S.J., Walker A.E., Cawthon R.M., Andtbacka R.H., Noyes D., et al. Role of arterial telomere dysfunction in hypertension: relative contributions of telomere shortening and telomere uncapping. J. Hypertens. 2014, 32(6):1293-1299.
18. Farrag W., Eid M., El-Shazly S., Abdallah M. Angiotensin II type 1 receptor gene polymorphism and telomere shortening in essential hypertension. Mol. Cell. Biochem. 2011, 351(1-2):13-18.
19. Pickett H.A., Reddel R.R. The role of telomere trimming in normal telomere length dynamics. Cell Cycle 2012, 11(7):1309-1315.
20. Allsopp R. Telomere length and iPSC re-programming: survival of the longest. Cell Res. 2012, 22(4):614-615.
21. Harte A.L., Silva N.F., Miller M.A., et al. Telomere length attrition, a marker of biological senescence, is inversely correlated with triglycerides and cholesterol in South Asian males with type 2 diabetes mellitus. Exp. Diabetes Res. 2012, 2012:895185.
22. Friedrich U., Griese E., Schwab M., et al. Telomere length in different tissues of elderly patients. Mech. Ageing Dev. 2000, 119(3):89-99.
23. Benetos A., Okuda K., Lajemi M., et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001, 37(2):381-385.
24. Xie L., Wang Y., Wen C., et al. Changes of leukocyte telomere length in peripheral blood of patients with hypertension. Chin. J. Gerontol. 2011, 31(8):2811-2814.
25. Lung F.W., Ku C.S., Kao W.T. Telomere length may be associated with hypertension. J. Hum. Hypertens. 2008, 22(3):230-232.
26. Yang Z., Huang X., Jiang H., et al. Short telomeres and prognosis of hypertension in a Chinese population. Hypertension 2009, 53(4):639-645.
27. Jeanclos E., Schork N.J., Kyvik K.O., et al. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension 2000, 36(2):195-200.
28. Leri A., Malhotra A., Liew C.C., et al. Telomerase activity in rat cardiac myocytes is age and gender dependent. J. Mol. Cell. Cardiol. 2000, 32(3):385-390.
29. Kurz D.J., Decary S., Hong Y., et al. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J. Cell Sci. 2004, 117(11):2417-2426.
30. Demissie S., Levy D., Benjamin E.J., et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham heart study. Aging Cell 2006, 5(4):325-330.
31. Sowers J.R., Frohlich E.D. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med. Clin. N. Am. 2004, 88(1):63-82.
32. Saad M.F., Rewers M., Selby J., et al. Insulin resistance and hypertension: the insulin resistance atherosclerosis study. Hypertension 2004, 43(6):1324-1331.
33. Benetos A., Gardner J.P., Zureik M., et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 2004, 43(2):182-185.
34. Fuster J.J., Andres V. Telomere biology and cardiovascular disease. Circ. Res. 2006, 99(11):1167-1180.
35. Ramachandran S.V., Serkalem D., Masayuki K., et al. Association of leukocyte telomere length with echocardiographic left ventricular mass: the Framingham heart study. Circulation 2009, 120(13):1195-1202.
36. Biotti D., Aho S., Béjot Y., et al. Leukocyte telomere length: a focus on cerebrovascular events. Rejuvenation Res. 2012, 15(3):274-280.
37. Edo M.D., Andrés V. Aging, telomeres, and therosclerosis. Cardiovasc. Res. 2005, 66(2):213-221.
38. Tristano A., Eugenia C.M., Willson M.L., et al. Telomerase activity in peripheral blood leukocytes from patients with essential hypertension. Med. Clin. 2003, 120(10):365-369.
39. Ouyang Y., Lu Y., Hu G. Telomerase activity of essential hypertension and the effect of Plendil and Rhodic. Lab. Med. 2004, 19(4):324-326.
40. Tan H., Li D., Huang M. Effect of antihypertensive therapy on telomerase activity of lymphocytes in patients with essential hypertension. Pract. Prev. Med. 2004, 11(4):667-669.
41. Birajalaxmi D., Nilambari P., Divyalakshmi S., et al. Genetic association study of selected candidate genes (ApoB, LPL, Leptin) and telomere length in obese and hypertensive individuals. BMC Med. Genet. 2009, 10(1):99.
42. Chen H., Shen X., Bai Y., et al. The peripheral telomerase activity of hypertensive patients. Chin. J. Hypertens. 2000, 8(1):28-30.
43. Fuster J.J., Díez J., Andrés V. Telomere dysfunction in hypertension. J. Hypertens. 2007, 25(11):2185-2192.
44. Nilsson P.M. Impact of vascular aging on cardiovascular disease: the role of telomere biology. J Hypertens 2012, S9-S12. (Suppl.:).